


Form PTO 1440 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 7732-020-27 DIV	SERIAL NO. 09/665,077
		APPLICANT MICHAEL CLIMO, ET AL.	RECEIVED APR 04 2001 TECH CENTER 1600/25
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE SEPTEMBER 19, 2000	GROUP ART UNIT 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
MV	AA	5,760,026	6/2/98	BLACKBURN, ET AL.			
	AB	5,858,962	1/99	BLACKBURN, ET AL.			
	AC	3,278,378	10/66	SCHINDLER ET AL.			
	AD	3,398,056	8/68	ZYGMUNT ET AL.			
	AE	3,594,284	7/71	ZYGMUNT ET AL.			
	AF	4,931,390	6/90	RECSEI			
MV	AG	6,028,051	2/00	CLIMO et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AH				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

MV	AI	Chambers, Henry F., "Parenteral Antibiotics for the Treatment of Bacteremia and Other Serious Staphylococcal Infections", The Staphylococci in Human Disease, Chapter 26, pages 583-595 (1997).
	AJ	Polak, et al., "In Vitro Activity of Recombinant Lysostaphin-Antibiotic Combinations Toward Methicillin-Resistant <i>Staphylococcus aureus</i> ", Diagn Microbiol Infect Dis, 17:265-270 (1993).
	AK	Berger-Bächi, Brigitte, "Resistance Not Mediated By β-Lactamase (Methicillin Resistance)", The Staphylococci in Human Disease, Grassley, et al. (eds), Chapter 6 (part 2), pages 158-174 (1997).
	AL	Tschierske, et al., "Lif, the Lysostaphin Immunity Factor, Complements FemB in Staphylococcal Peptidoglycan Interpeptide Bridge Formation", FEMS Microbiology Letters, Volume 153, pages 261-264 (1997).
	AM	DeHart, et al., "The Lysostaphin Endopeptidase Resistance Gene (epr) Specifies Modification of Peptidoglycan Cross Bridges in <i>Staphylococcus simulans</i> and <i>Staphylococcus aureus</i> ", Applied and Environmental Microbiology, Volume 61, No. 4, pages 1475-1479, April 1995.
	AN	Strandén, et al., "Cell Wall Monoglycine Cross-Bridges and Methicillin Hypersusceptibility in a <i>femAB</i> Null Mutant of Methicillin-Resistant <i>Staphylococcus aureus</i> ", Journal of Bacteriology, Volume 179, No. 1, pages 9-16, January 1997.
MV	AO	Zygmunt, et al., "Lytic Action of Lysostaphin on Susceptible and Resistant Strains of <i>Staphylococcus Aureus</i> ", Canadian Journal of Microbiology, Volume 13, pages 845-853 (1967).

EXAMINER

DATE CONSIDERED 02/02

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 7732-020-27 DIV	SERIAL NO. 09/665,077
		APPLICANT MICHAEL CLIMO, ET AL.	RECEIVED APR 04 2001
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE SEPTEMBER 19, 2000	TECH CENTER 1600/290 GROUP ART UNIT 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AP						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	AQ				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

MR	AR	Ehlert, et al., "Specificities of FemA and FemB for Different Glycine Residues: FemB Cannot Substitute for FemA in Staphylococcal Peptidoglycan Pentaglycine Side Chain Formation", Journal of Bacteriology, Volume 179, No. 23, pages 7573-7576 (December 1997).
	AS	Dixon, et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. III. Lystostaphin-Methicillin Therapy of Established Staphylococcal Abscesses in Mice", Yale Journal of Biology and Medicine, Volume 41, pages 62-68, August 1968.
	AT	Schaffner, et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. II. Lysostaphin, in vivo Studies", Yale Journal of Biology and Medicine, Volume 39, pages, 230-244, February 1967.
	AU	Schaffner, et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. I. Lysostaphin in vitro Studies", Yale Journal of Biology and Medicine, Volume 39, pages 215-229, February 1967.
	AV	Kessler, et al., "Secreted LasA of <i>Pseudomonas aeruginosa</i> Is a Staphylolytic Protease", The Journal of Biological Chemistry, Volume 268, No. 10, pages 7503-7508 (1993).
	AW	Li, et al., "Purification, Staphylolytic Activity, and Cleavage Sites of α -Lytic Protease from <i>Achromobacter lyticus</i> ", The Journal of Biological Chemistry, Volume 122, No. 4, pages 772-778 (1997).
	AX	Oldham, et al., "Lysostaphin: Use of a Recombinant Bactericidal Enzyme as a Mastitis Therapeutic", J. Diary of Sci., 74:4175-4182 (1991).
	AY	Martin, et al., "The Selective Activity of Lysotaphin in vivo", The Journal of Laboratory and Clinical Medicine, Volume 70, No. 1, pages 1-8 (July 1967).
	AZ	Martin, et al., "The Reacquisition of Staphylococci by Treated Carriers: A Demonstration of Bacterial Interference", J. Lab. Clin. Med., Volume 71, No. 5, pages 791-797 (May 1968).
MR	BA	Harrison et al., "Therapeutic Activity of Lysostaphin in Experimental Staphylococcal Infections", Canadian Journal of Microbiology, Volume 13, pages 93-97 (1967).

EXAMINER	<i>AB</i>	DATE CONSIDERED
----------	-----------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 7732-020-27 DIV	SERIAL NO. 09/665,077
APR 03 2001 PATENT & TRADEMARK OFFICE APPLICANT MICHAEL CLIMO, ET AL.			
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE SEPTEMBER 19, 2000	GROUP ART UNIT 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	BC				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

MW	BD	Schuhardt, et al., "Lysostaphin Therapy in Mice Infected with <i>Staphylococcus Aureus</i> ", J. Bacteriol., Volume 88, No. 1064, pages 815-816.
	BE	Harrison, et al., "Lysostaphin in Experimental Renal Infections", Journal of Bacteriology, pages 520-524, (February 1967).
	BF	Stark, et al., "Systemic Lysostaphin Man - Apparent Antimicrobial Activity in A Neutropenic Patient", The New England Journal of Medicine, pages 239-240 (August 1974).
	BG	Goldberg et al., "Studies in Experimental Staphylococcal Endocarditis in Dogs. VI. Treatment in Lysostaphin", Antimicrobial Agents and Chemotherapy, pages 45-53 (1967).
MW	BH	Quickel, Jr. et al, "Efficacy and Safety of Topical Lysostaphin Treatment of Persistent Nasal Carriage of <i>Staphylococcus aureus</i> ", Applied Microbiology, pages 446-450 (September 1971).
	BI	
	BJ	
	BK	
	BL	
	BM	
	BN	
	BO	
	BP	
	BQ	
	BR	
	BS	
	BT	

EXAMINER

*Robert*DATE CONSIDERED 07/02

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.